InvestorsHub Logo
Followers 8
Posts 309
Boards Moderated 0
Alias Born 06/23/2011

Re: hankmanhub post# 599058

Wednesday, 06/07/2023 9:13:58 AM

Wednesday, June 07, 2023 9:13:58 AM

Post# of 700269
Surely this would only be of benefit to the recipient if it could be ensured that only malignant epitopes / peptides from the tumour would be used to sensitise the dendrocytes. The patients own dendrocytes automatically recognise what is self (and do not react) and what is non-self (malignantly transformed cells), becoming sensitised to that foreign tissue.

It is inevitable that in any biopsy/excision of malignant tissue, normal cells and tissue is included with the abnormal. If dendrocytes from a non-identical "donor" are used the dendrocytes would be sensitised not only to malignant (therefore "foreign") epitopes / peptides but also to the patient's normal tissue which will be recognise as being non-self (ie foreign to the dendrocytes). Injecting those sensitised dendrocytes into the recipient will result in what is essentially a graft-vs-host reaction, potentially causing multi-organ damage should the injected clones of dendrocytes become established in the recipients immune system. .
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent NWBO News